

## FORM 51-102F3

### MATERIAL CHANGE REPORT

#### ***Item 1 – Name and Address of Company***

NurExone Biologic Inc. (formerly EnerSpar Corp.) (the “**Company**”)  
421 7<sup>th</sup> Avenue SW, Suite 1600  
Calgary, Alberta, T2P 4K9

#### ***Item 2 – Date of Material Change***

December 6, 2022

#### ***Item 3 – News Release***

The press release disclosing the material change was released on December 7, 2022 through the services of Newsfile Corp.

#### ***Item 4 – Summary of Material Change***

The Company completed its securities for debt settlement on December 6, 2022, previously announced by the Company on November 24, 2022.

The Company agreed to settle debts in the aggregate amount of CAD\$46,523.69 with the issuance of 122,430 common shares of the Company at a deemed price of CAD\$0.38 per share. The common shares issued are subject to a four-month plus one-day hold period pursuant to the policies of the TSX Venture Exchange.

#### ***Item 5 – Full Description of Material Change***

##### ***5.1 – Full Description of Material Change***

On November 24, 2022, the Company announced that it agreed to offer 122,430 common shares of the Company at a deemed price of CAD\$0.38 per share to settle indebtedness of CAD\$46,523.69. The debts were incurred prior to the recent Reverse Takeover Transaction following which the Company began trading under the new name "NurExone Biologic Inc." with the trading symbol "NRX".

On December 7, 2022, the Company announced that it completed its securities for debt settlement on December 6, 2022. The common shares issued are to a four-month plus one-day hold period pursuant to the policies of the TSX Venture Exchange.

##### ***5.2 – Disclosure for Restructuring Transactions***

Not applicable

#### ***Item 6 – Reliance on subsection 7.1(2) of National Instrument 51-102***

Not applicable.

**Item 7 – Omitted Information**

No information has been omitted from this material change report.

**Item 8 – Executive Officer**

Dr. Lior Shaltiel  
Chief Executive Officer  
+972-52-4803034

**Item 9 – Date of Report**

December 7, 2022